February 6, 2023

A new method (BloodFlow) was developed to increase the negative predictive value and showed an unprecedented sensitivity to detect MRD.

February 2, 2023

A recent study provided strong evidence for intensification of therapy in patients with high-risk myeloma determined by their genetic profile.

January 29, 2023

A study evaluates responses to the SARS-CoV-2 vaccination among myeloma patients.

January 24, 2023

The MonumenTAL study shows durable responses with Talquetamab for relapsed/refractory myeloma

January 24, 2023

An ongoing trial is using a more intense regimen to treat high-risk smoldering myeloma patients.

January 19, 2023

Immunotherapy research in myeloma is exploding, evidenced by the MagnetisMM family of studies updated at ASH.

January 19, 2023

New bispecific combinations in clinical trials show promise for relapsed/refractory myeloma

January 17, 2023

A NEX-T generation BCMA targeted CAR T for multiple myeloma is being studied that includes shorter processing time and better impact..

January 16, 2023

The MRD2STOP research shows promise for a potential end to maintenance.

January 9, 2023

Cevostamab shows promising results in heavily pretreated multiple myeloma patients according to a recent presentation at ASH 2022.